Opportunity Information: Apply for PAR 22 037
This NIH grant opportunity (PAR 22-037) supports R01 research projects aimed at clarifying how astrocytes contribute to degeneration of the neurovascular unit in Alzheimer’s disease and related dementias (AD/ADRDs), with a specific emphasis on basic and mechanistic work rather than clinical trials (the funding announcement explicitly states "Clinical Trial Not Allowed"). The central idea behind the opportunity is that the neurovascular unit, which includes brain endothelial cells, pericytes, vascular smooth muscle cells, neurons, astrocytes, microglia, and extracellular matrix components, is involved in multiple biological pathways that can drive neurodegeneration. Within this system, astrocytes stand out as especially important because they sit at the crossroads of blood-brain barrier regulation, neuronal support, inflammatory and stress responses, and the brain’s reaction to injury and accumulating pathology. Because astrocytes physically and functionally interface with both blood vessels and neurons, they are positioned as promising therapeutic targets, but the field still lacks a clear, causal, mechanistic understanding of what astrocytes are doing in the neurovascular unit during health, aging, and disease.
A major motivation for the program is a recognized knowledge gap: while astrocytes are known to influence blood-brain barrier integrity and participate in APOE-related signaling (highly relevant given APOE’s strong genetic linkage to AD risk), their precise mechanistic roles in neurovascular dysfunction across the AD/ADRD spectrum remain poorly defined. This includes their potential involvement in vascular contributions to cognitive impairment and dementia (VCID), a broad category that captures how cerebrovascular disease and blood flow, vessel integrity, and barrier breakdown can contribute to cognitive decline either independently or alongside classic AD pathology. The announcement frames this gap as a clear opportunity for targeted investment, and it is described as the first NIH initiative specifically focused on the fundamental role of astrocytes in AD/ADRD, signaling an intent to stimulate a critical mass of work in this area and build a stronger mechanistic foundation for future therapies.
From an administrative and funding standpoint, the mechanism is a discretionary NIH research grant (R01) in the health area, associated with CFDA numbers 93.853 and 93.866. The listed award ceiling is $500,000, and the original closing date provided in the source data is 2022-02-04. The opportunity is open to a wide range of applicant organizations, including state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized tribal governments; tribal organizations that are not federally recognized; public housing and Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses, among others. The announcement also highlights additional eligible applicant categories often emphasized in NIH participation goals, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), faith-based or community-based organizations, U.S. territories or possessions, regional organizations, eligible federal agencies, and even non-U.S. entities (foreign organizations).
In practical terms, the research this call is trying to catalyze is work that explains "how" and "why" astrocytes drive neurovascular unit breakdown or dysfunction in AD/ADRDs and VCID-relevant conditions, and how those astrocyte-driven changes relate to downstream neuronal injury, cognitive decline, and disease progression. The emphasis on mechanism implies projects may focus on astrocyte interactions with blood-brain barrier components, astrocyte-mediated inflammatory signaling, metabolic and trophic support roles, effects on vascular tone and cerebral blood flow regulation, and the ways astrocytes respond to or amplify pathology linked to APOE and other AD/ADRD risk factors. The overall goal is to move beyond association and toward causal explanations that can reveal testable therapeutic strategies centered on astrocyte biology within the neurovascular unit.Apply for PAR 22 037
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
- This funding opportunity was created on 2021-09-30.
- Applicants must submit their applications by 2022-02-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR 22-037 (R01) - Astrocytes and Neurovascular Unit Degeneration in AD/ADRD
What is this grant opportunity (PAR 22-037) focused on?
This NIH funding opportunity supports R01 research projects that clarify how astrocytes contribute to degeneration or dysfunction of the neurovascular unit in Alzheimer's disease and related dementias (AD/ADRDs). The emphasis is on basic and mechanistic research that explains causal roles and biological mechanisms, rather than descriptive associations.
What is the overall scientific goal of the program?
The program aims to build a mechanistic foundation for understanding how astrocytes influence neurovascular unit breakdown across health, aging, and disease. By moving beyond correlation and toward causal explanations, the program seeks to enable future, testable therapeutic strategies centered on astrocyte biology within the neurovascular unit.
What kinds of studies are encouraged by the "basic and mechanistic" emphasis?
Projects are expected to address "how" and "why" astrocytes drive neurovascular dysfunction, including mechanistic links to downstream neuronal injury, cognitive decline, and disease progression. Mechanistic work may include studies of astrocyte interactions with blood-brain barrier components, inflammatory and stress signaling, metabolic and trophic support, regulation of vascular tone and cerebral blood flow, and responses to or amplification of pathology related to APOE and other AD/ADRD risk factors.
Are clinical trials allowed under this funding announcement?
No. The announcement explicitly states "Clinical Trial Not Allowed."
What funding mechanism is being used?
The opportunity uses the NIH R01 mechanism, which supports discrete research projects. It is described as a discretionary NIH research grant in the health area.
What is the award ceiling listed for this opportunity?
The listed award ceiling is $500,000.
What is the relevance of the neurovascular unit to AD/ADRD?
The neurovascular unit includes brain endothelial cells, pericytes, vascular smooth muscle cells, neurons, astrocytes, microglia, and extracellular matrix components. This system participates in multiple biological pathways that can drive neurodegeneration, including processes affecting vessel integrity, blood-brain barrier function, inflammatory responses, and neuronal support.
Why are astrocytes a central focus of this opportunity?
Astrocytes sit at the crossroads of blood-brain barrier regulation, neuronal support, inflammatory and stress responses, and the brain's response to injury and accumulating pathology. Because they physically and functionally interface with both blood vessels and neurons, they are positioned as especially important drivers (and potential therapeutic targets) in neurovascular unit dysfunction.
What knowledge gap is this program trying to address?
While astrocytes are known to influence blood-brain barrier integrity and participate in APOE-related signaling, their precise mechanistic roles in neurovascular dysfunction across the AD/ADRD spectrum remain poorly defined. This opportunity is intended to close that gap by encouraging causal, mechanistic studies of astrocytes in neurovascular unit degeneration.
How does APOE relate to the goals of this grant?
APOE is highlighted because it has a strong genetic linkage to Alzheimer's disease risk, and astrocytes participate in APOE-related signaling. The program notes that astrocyte involvement in APOE-linked pathways is relevant to understanding neurovascular dysfunction in AD/ADRD, but emphasizes that precise mechanisms are still not clearly defined.
Does this opportunity include vascular contributions to cognitive impairment and dementia (VCID)?
Yes. The announcement discusses VCID as a related area of interest, capturing how cerebrovascular disease, blood flow changes, vessel integrity problems, and blood-brain barrier breakdown can contribute to cognitive decline either independently or alongside classic AD pathology. Mechanistic work that clarifies astrocyte roles in VCID-relevant neurovascular dysfunction aligns with the stated motivation of the program.
What types of downstream outcomes are considered relevant in proposed studies?
The call emphasizes connecting astrocyte-driven neurovascular unit changes to downstream neuronal injury, cognitive decline, and disease progression. The intent is to link mechanistic events at the neurovascular interface to meaningful neurodegenerative outcomes.
Who is eligible to apply?
The opportunity is open to a broad set of applicant organizations, including state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized tribal governments; tribal organizations that are not federally recognized; public housing and Indian housing authorities; nonprofits (501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses, among others.
Are organizations with NIH participation goals specifically mentioned as eligible?
Yes. The eligibility description highlights categories frequently emphasized in NIH participation goals, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and eligible federal agencies.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The eligibility information explicitly includes non-U.S. entities (foreign organizations).
What is the CFDA information associated with this opportunity?
The opportunity is associated with CFDA numbers 93.853 and 93.866.
What closing date is listed in the source information?
The original closing date provided in the source data is 2022-02-04.
Why does the announcement describe this as a notable NIH initiative?
It is described as the first NIH initiative specifically focused on the fundamental role of astrocytes in AD/ADRD. The stated intent is to stimulate a critical mass of work in this area and strengthen the mechanistic foundation needed for future therapies.
What kinds of neurovascular unit components might be considered when designing a project?
The neurovascular unit is described as including brain endothelial cells, pericytes, vascular smooth muscle cells, neurons, astrocytes, microglia, and extracellular matrix components. Proposals may consider astrocyte interactions with these components to explain neurovascular dysfunction and its consequences in AD/ADRD.
What is the practical impact the program hopes to achieve?
By clarifying causal mechanisms for astrocyte-driven neurovascular unit degeneration, the program aims to reveal testable therapeutic strategies that target astrocyte biology and its effects on blood-brain barrier regulation, vascular function, and neuronal health in AD/ADRD and related vascular contributions to cognitive decline.
Browse more opportunities from the same category: Health
Next opportunity: Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Previous opportunity: The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 037
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 037) also looked into and applied for these:
| Funding Opportunity |
|---|
| Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed) Apply for PAR 21 312 Funding Number: PAR 21 312 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| SPARC Human Open Research Neural Engineering Technologies (HORNET) Initiative (U41 Clinical Trial Not Allowed) Apply for RFA RM 21 024 Funding Number: RFA RM 21 024 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neurosurgeon Research Career Development Program (NRCDP) (K12 Independent Clinical Trial Not Allowed) Apply for RFA NS 21 019 Funding Number: RFA NS 21 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional) Apply for PAR 22 025 Funding Number: PAR 22 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| IDeA Regional Entrepreneurship Development (I-RED) Program (STTR) (UT2 Clinical Trial Not Allowed) Apply for RFA GM 22 001 Funding Number: RFA GM 22 001 Agency: National Institutes of Health Category: Health Funding Amount: $252,000 |
| Pilot Practice-based Research for Primary Care Suicide Prevention (R34 Clinical Trial Optional) Apply for RFA MH 22 120 Funding Number: RFA MH 22 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed) Apply for PAR 22 034 Funding Number: PAR 22 034 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) Apply for PAR 21 321 Funding Number: PAR 21 321 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) Apply for PAR 22 048 Funding Number: PAR 22 048 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed) Apply for PAR 22 039 Funding Number: PAR 22 039 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required) Apply for PAR 22 040 Funding Number: PAR 22 040 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) Apply for PAR 22 038 Funding Number: PAR 22 038 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Advancing Group A Streptococcus Vaccine Discovery (R01 Clinical Trial Not Allowed) Apply for RFA AI 21 070 Funding Number: RFA AI 21 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Expanding Differentiated Care Approaches for Adolescents Living with HIV (R01 Clinical Trial Optional) Apply for RFA MH 22 105 Funding Number: RFA MH 22 105 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Digital Health Strengthening in Eswatini Apply for RFI67421ESWATINIHEALTHINFORMATIONSYSTEM Funding Number: RFI67421ESWATINIHEALTHINFORMATIONSYSTEM Agency: South Africa USAID-Pretoria Category: Health Funding Amount: Case Dependent |
| Enhanced Interpersonal Focused Strategies for Suicide Prevention Interventions (R34 Clinical Trial Required) Apply for RFA MH 22 125 Funding Number: RFA MH 22 125 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Identification and Characterization of Persistence Mechanisms of Select Protozoan Pathogens (R01 Clinical Trial Not Allowed) Apply for RFA AI 21 075 Funding Number: RFA AI 21 075 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Expanding Differentiated Care Approaches for Adolescents Living with HIV (R34 Clinical Trial Optional) Apply for RFA MH 22 106 Funding Number: RFA MH 22 106 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional) Apply for RFA AG 23 001 Funding Number: RFA AG 23 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cellular Senescence Network: Murine Tissue Mapping Centers (U54 - Clinical Trial Not Allowed) Apply for RFA RM 22 003 Funding Number: RFA RM 22 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 037", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.